Acupuncture and osteopathic medicine for atopic dermatitis: a three-armed, randomized controlled explorative clinical trial.


Journal

Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847

Informations de publication

Date de publication:
Dec 2022
Historique:
accepted: 19 07 2022
pubmed: 26 7 2022
medline: 30 11 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

Patients with atopic dermatitis (AD) frequently use acupuncture (ACU) and osteopathic medicine (OM), although their therapeutic benefits are unclear. To investigate the effectiveness of ACU and OM in patients with AD. In a three-armed, single-centre, randomized controlled open explorative clinical trial, adult patients with AD received ACU, OM or no study intervention (control group; CG) plus routine care. Outcomes included disease severity (SCORing Atopic Dermatitis; SCORAD), itching intensity (visual analogue scale; VAS), frequency of topical corticosteroid (TCS) use over 7 days and cost-effectiveness. Endpoints were analysed by analysis of covariance adjusted for the respective baseline value and TCS use. Overall, 121 patients (92 women, 29 men) with a mean ± SD age of 31.4 ± 10.5 years were randomized. After 12 weeks, the adjusted means (95% CI) for ACU, OM and control were, respectively, 22.3 (18.3-26.3), 26.4 (22.6-30.2) and 23.7 (19.9-27.5) for SCORAD (P = 0.32); 27.9 (19.5-36.4), 35.0 (26.9-43.0) and 42.3 (34.7-50.0) for VAS itching (P < 0.05); and 2.3 (0.8-3.9), 1.9 (0.4-3.5) and 4.3 (2.6-6.0), for TCS use (P = 0.10). ACU and OM were not cost-effective compared with the CG. Although no differences in disease severity were found, our findings indicate that ACU might reduce itching in patients with AD. Furthermore, ACU and OM showed a trend towards reducing TCS use.

Sections du résumé

BACKGROUND BACKGROUND
Patients with atopic dermatitis (AD) frequently use acupuncture (ACU) and osteopathic medicine (OM), although their therapeutic benefits are unclear.
AIM OBJECTIVE
To investigate the effectiveness of ACU and OM in patients with AD.
METHODS METHODS
In a three-armed, single-centre, randomized controlled open explorative clinical trial, adult patients with AD received ACU, OM or no study intervention (control group; CG) plus routine care. Outcomes included disease severity (SCORing Atopic Dermatitis; SCORAD), itching intensity (visual analogue scale; VAS), frequency of topical corticosteroid (TCS) use over 7 days and cost-effectiveness. Endpoints were analysed by analysis of covariance adjusted for the respective baseline value and TCS use.
RESULTS RESULTS
Overall, 121 patients (92 women, 29 men) with a mean ± SD age of 31.4 ± 10.5 years were randomized. After 12 weeks, the adjusted means (95% CI) for ACU, OM and control were, respectively, 22.3 (18.3-26.3), 26.4 (22.6-30.2) and 23.7 (19.9-27.5) for SCORAD (P = 0.32); 27.9 (19.5-36.4), 35.0 (26.9-43.0) and 42.3 (34.7-50.0) for VAS itching (P < 0.05); and 2.3 (0.8-3.9), 1.9 (0.4-3.5) and 4.3 (2.6-6.0), for TCS use (P = 0.10). ACU and OM were not cost-effective compared with the CG.
CONCLUSION CONCLUSIONS
Although no differences in disease severity were found, our findings indicate that ACU might reduce itching in patients with AD. Furthermore, ACU and OM showed a trend towards reducing TCS use.

Identifiants

pubmed: 35875898
doi: 10.1111/ced.15340
doi:

Substances chimiques

Dermatologic Agents 0
Adrenal Cortex Hormones 0

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2166-2175

Subventions

Organisme : Deutsche Neurodermitis Stiftung

Informations de copyright

© 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Références

Jenner N, Campbell J, Marks R. Morbidity and cost of atopic eczema in Australia. Australas J Dermatol 2004; 45: 16-22.
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (Association of the Scientific Medical Societies in Germany). Guidelines of the German Dermatological Society (DDG) and the Professional Association of German Dermatologists (BVDD): Guideline Neurodermatitis [atopic eczema; atopic dermatitis. AWMF Register Number: 013-02. 23014.] (in German). Available at: https://www.awmf.org/leitlinien/detail/ll/013-027.html (accessed 25 August 2022).
Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15; quiz 6-8.
Kim GW, Park JM, Chin HW et al. Comparative analysis of the use of complementary and alternative medicine by Korean patients with androgenetic alopecia, atopic dermatitis and psoriasis. J Eur Acad Dermatol Venereol 2013; 27: 827-35.
Napadow V, Li A, Loggia ML et al. The brain circuitry mediating antipruritic effects of acupuncture. Cereb Cortex 2014; 24: 873-82.
Pfab F, Huss-Marp J, Gatti A et al. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial. Allergy 2010; 65: 903-10.
Ruffini N, D'Alessandro G, Mariani N et al. Variations of high frequency parameter of heart rate variability following osteopathic manipulative treatment in healthy subjects compared to control group and sham therapy: randomized controlled trial. Front Neurosci 2015; 9: 272.
Pieper M. Osteopathy in atopic dermatitis in adults. A pilot study (in German). Osteopathy School Germany Thesis for Bachelor of Science, Dresden International University, 2016.
Hosono S, Fujita K, Nimura A, Akita K. Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: a case series. JAAD Case Rep 2020; 6: 510-13.
Williams HC, Burney PG, Hay RJ et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131: 383-96.
Wolkerstorfer A, de Waard van der Spek FB, Glazenburg EJ et al. Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol 1999; 79: 356-9.
Schram ME, Spuls PI, Leeflang MM et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99-106.
Riepe C, Osada N, Reich A et al. Minimal clinically important difference in chronic pruritus appears to be dependent on baseline itch severity. Acta Derm Venereol 2019; 99: 1288-90.
Basra MK, Salek MS, Camilleri L et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: 27-33.
Resnick B, Nahm ES. Reliability and validity testing of the revised 12-item Short-Form Health Survey in older adults. J Nurs Meas 2001; 9: 151-61.
Zisapel N, Nir T. Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale. J Sleep Res 2003; 12: 291-8.
Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004; 42: 851-9.
Hwang J, Lio PA. Acupuncture in dermatology: an update to a systematic review. J Altern Complement Med 2021; 27: 12-23.
Salameh F, Perla D, Solomon M et al. The effectiveness of combined Chinese herbal medicine and acupuncture in the treatment of atopic dermatitis. J Altern Complement Med 2008; 14: 1043-8.
Schwaneberg T, Witt CM, Roll S, Pach D. Comparing physicians' and patients' reporting on adverse reactions in randomized trials on acupuncture-a secondary data analysis. BMC Complement Altern Med 2019; 19: 223.
Degenhardt BF, Johnson JC, Brooks WJ, Norman L. Characterizing adverse events reported immediately after osteopathic manipulative treatment. J Am Osteopath Assoc 2018; 118: 141-9.
Ortiz M, Witt CM, Binting S et al. A randomised multicentre trial of acupuncture in patients with seasonal allergic rhinitis - trial intervention including physician and treatment characteristics. BMC Complement Altern Med 2014; 14: 128.
Verhaeghe N, Schepers J, van Dun P, Annemans L. Osteopathic care for spinal complaints: a systematic literature review. PLoS One 2018; 13: e0206284.
Moustgaard H, Clayton GL, Jones H et al. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. BMJ 2020; 368: l6802.
Brinkhaus B, Ortiz M, Witt CM et al. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med 2013; 158: 225-34.

Auteurs

Gabriele Rotter (G)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Moritz W Ahnert (MW)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Anne V Geue (AV)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Katja Icke (K)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Sylvia Binting (S)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Tatjana Tissen-Diabaté (T)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Stephanie Roll (S)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Miriam Ortiz (M)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Thomas Reinhold (T)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Benjamin Kass (B)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Doris Staab (D)

Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Florian Pfab (F)

Medzentrum Residenz, Munich, Germany.

Stefan N Willich (SN)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Benno Brinkhaus (B)

Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH